View ValuationInterCure 将来の成長Future 基準チェック /06現在、 InterCureの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長15.0%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesReported Earnings • May 05Full year 2025 earnings released: ₪0.66 loss per share (vs ₪1.48 loss in FY 2024)Full year 2025 results: ₪0.66 loss per share (improved from ₪1.48 loss in FY 2024). Revenue: ₪270.2m (up 13% from FY 2024). Net loss: ₪35.7m (loss narrowed 47% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has only fallen by 33% per year, which means it has not declined as severely as earnings.New Risk • Apr 26New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 25% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Share price has been volatile over the past 3 months (7.3% average weekly change). Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (₪140.8m market cap, or US$47.2m).New Risk • Apr 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Israeli stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 25% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.1% average weekly change). Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (₪148.7m market cap, or US$49.5m).分析記事 • Jan 14Why Investors Shouldn't Be Surprised By InterCure Ltd.'s (TLV:INCR) 29% Share Price PlungeUnfortunately for some shareholders, the InterCure Ltd. ( TLV:INCR ) share price has dived 29% in the last thirty days...分析記事 • Dec 24We Discuss Why InterCure Ltd.'s (TLV:INCR) CEO Compensation May Be Closely ReviewedKey Insights InterCure's Annual General Meeting to take place on 30th of December Total pay for CEO Alex Rabinovich...New Risk • Dec 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Israeli stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 25% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.5% average weekly change). Shareholders have been diluted in the past year (19% increase in shares outstanding). Market cap is less than US$100m (₪224.3m market cap, or US$70.0m).お知らせ • Nov 26InterCure Ltd., Annual General Meeting, Dec 30, 2025InterCure Ltd., Annual General Meeting, Dec 30, 2025. Location: amit, pollak, matalon & co., at apm house, 18 raoul wallenberg st., building d, 6th floor, ramat hachayal., tel aviv IsraelReported Earnings • Oct 11First half 2025 earnings released: ₪0.03 loss per share (vs ₪0.03 profit in 1H 2024)First half 2025 results: ₪0.03 loss per share (down from ₪0.03 profit in 1H 2024). Revenue: ₪130.0m (up 3.4% from 1H 2024). Net loss: ₪1.70m (down 219% from profit in 1H 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 61 percentage points per year, which is a significant difference in performance.Board Change • Aug 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. Non-Executive Director Alon Granot was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • May 02InterCure Ltd. announced delayed 20-F filingOn 05/01/2025, InterCure Ltd. announced that they will be unable to file their next 20-F by the deadline required by the SEC.お知らせ • Feb 13Intercure Names Announces Board Changes, Effective February 13, 2025InterCure Ltd. announces that Mr. Ehud Barak will step down as Chairman of the board of directors of the Company, effective February 13, 2025. He will be succeeded by Mr. Alexander Rabinovich, who has successfully led the Company as CEO for the past five years, executing hundreds of percentages of profitable growth, building strategic international partnerships, and establishing InterCure's position as a leader in pharmaceutical cannabis. Mr. Barak, who is marking his 83rd birthday, has decided to pursue personal endeavors after six years of service as Chairman of their Board. InterCure extends its deepest appreciation to Mr. Barak for his contributions, which has helped guide the Company's progress alongside its executive team.お知らせ • Nov 26InterCure Ltd., Annual General Meeting, Dec 30, 2024InterCure Ltd., Annual General Meeting, Dec 30, 2024. Location: at the offices of the companys attorneys, doron tikotzky kantor gutman & amit gross., 7 metsada st., b.s.r tower 4, 33 floor, bnei brak Israelお知らせ • May 03+ 1 more updateInterCure Ltd. announced delayed 20-F filingOn 05/01/2024, InterCure Ltd. announced that they will be unable to file their next 20-F by the deadline required by the SEC.お知らせ • Feb 15InterCure Ltd. Announces Resignation of Rami Levy as Chief of OperationsInterCure Ltd. announced that effective February 7, 2024, Rami Levy, resigned as the Chief of Operations of the company due to personal reasons. Mr. Levy’s resignation was not the result of any disagreement with the Company, or due to any matter relating to the Company’s operations, policies or practices.お知らせ • Nov 09InterCure Ltd., Annual General Meeting, Dec 14, 2023InterCure Ltd., Annual General Meeting, Dec 14, 2023, at 16:00 Israel Standard Time. Location: the offices of the Company's attorneys, Doron Tikotzky Kantor Gutman Nass & Amit Gross., 7 Metsada St., lB.S.R Tower 4, 33 Floor, Bnei Brak, Israe Bnei Brak Israel Agenda: To approve the re-election of Ehud Barak, Alexander Rabinovich, and Alon Granot, to the board of directors of the Company, each until the next annual general meeting of shareholders ; to approve, upon the recommendation of the Company's audit committee and of the Board of Directors, the re-election of David Salton to our Board of Directors, as an independent director until the next annual general meeting of shareholders; to approve the re-appointment of Somekh Chaikin, a member firm of KPMG International (the "Auditors"), as the Company's independent registered public accounting firm for the year ending December 31, 2023, and to authorize the Board of Directors, upon the recommendation of the Audit Committee, to determine the Auditors' remuneration to be fixed in accordance with the volume and nature of their services to the Company for such fiscal year; and to consider other matters if any.お知らせ • Nov 01InterCure Ltd. Wins Cannolam Arbitration ProceedingInterCure Ltd. reported that, further to the Company's press release issued on August 31, 2023, in which the Company reported that the Tel Aviv-Jaffa District Court dismissed the lawsuit that filed against the Company by minority shareholders of its subsidiary, Cannolam Ltd. (‘Cannolam’), and the parties agreed on a binding arbitration process (the ‘Arbitration’), in which the amount owed to the Company and the parties will be determined and paid as part of a full separation process, the Company hereby reports that the Arbitration has been concluded, and the arbitrator has decided in favor of the Company on most of the claims presented to him by the Company, while rejecting almost all of the claims presented by the minority shareholders. Additionally, the arbitrator determined that Cannolam owes InterCure significant amounts (tens of NIS millions), which InterCure has claimed as part of the Arbitration, in recognition of InterCure's ongoing support to Cannolam. The minority shareholders did not transfer their part of the Cannolam debt owed to InterCure, and as a result, in accordance with the Arbitration decision, their shares in Cannolam were transferred to InterCure. As a result, as of the date hereof, InterCure now holds 100% of the shares in Cannolam, which has the exclusive right to use the ‘CookiesTM’ brand in Israel and other territories. Cannolam is the leading pharmacy chain specializing in dispensing pharmaceutical-grade cannabis. It operates under GivolTM and CookiesTM branded locations.お知らせ • Jul 12InterCure Announces Proposed Voluntary Delisting from the Toronto Stock ExchangeInterCure Ltd. ("InterCure" or the "Company"), announced that its board of directors (“Board”) has approved the voluntarily delisting of the Company’s common shares (“Shares”) from the Toronto Stock Exchange (the “TSX”) (the “Delisting”). The Company has decided to delist from the TSX after concluding that maintaining the listing does not offer substantial benefits to the Company and its shareholders. The Shares are currently listed on the NASDAQ and the Tel Aviv Stock Exchange, in addition to them being listed on the TSX. After a careful review of the trading volume data relating to the Shares, the Board has concluded that the trading volume on the TSX in insufficient to justify the continued listing. The Issuer will, however, remain a “reporting issuer” under applicable Canadian securities laws and continue to provide regular comprehensive disclosure pursuant to National Instrument 71-102 – Continues Disclosure and Other Exemptions Relating to Foreign Issuers as a “SEC Foreign Issuer”. Most brokers in Canada, including discount and online brokers, have the ability to buy and sell securities listed on the NASDAQ. Therefore, the Company’s NASDAQ listing will continue to provide shareholders with the same accessibility to trade the Company’s common shares. The value of the Company’s common shares is not related to or dependent on the TSX listing. Shareholders holding common shares in Canadian brokerage accounts should contact their brokers to confirm how to trade the Company’s shares on the NASDAQ. The Company has applied to the TSX to delist the Shares from the TSX at the end of the trading session on August 14, 2023. The Delisting is subject to the approval of the TSX. As per Section 720 of the TSX Company Manual, shareholder approval is not required as an acceptable alternate market exists for the listed securities. In connection with the Delisting, in accordance with Israeli securities laws, the Company will seek the approval of its shareholders, at a special meeting of shareholders called on August 14, 2023, to rely on the dual listing of the Shares on the Nasdaq Global Market and on Tel Aviv Stock Exchange for the purposes of compliance with Israeli securities laws, in accordance with Section 35FF of the Israeli Securities Law, 5728-1968.お知らせ • Jun 15Better Files A Lawsuit Against InterCure and its Chairman Ehud BarakMedical cannabis company Better is suing InterCure, a company headed by Ehud Barak, for $35 million. A lawsuit has been filed against InterCure and its management, adding to a series of lawsuits recently filed against the company's conduct. According to Better, the lawsuit stems from InterCure's alleged attempts to push competitors like Better and other cannabis companies out of the market. Better claims that InterCure has a history of misrepresenting facts to acquisition companies for the purpose of merging and abusing its power in the deal. Better also claims that InterCure has the bad faith of engaging in predatory activities that drain the financial reserves of the acquisition targets. The lawsuit addresses the actions taken by InterCure's executives during the negotiations with Better, allegedly including making false representations, exerting pressure to transfer commercial materials, damaging production capabilities and harming the company's customers, assets, and means. Better is asking the court for a number of remedies outlined in its lawsuit, as compensation for InterCure's damages to Better during negotiations.Reported Earnings • May 17First quarter 2023 earnings released: EPS: ₪0.005 (vs ₪0.38 in 1Q 2022)First quarter 2023 results: EPS: ₪0.005 (down from ₪0.38 in 1Q 2022). Revenue: ₪106.2m (up 22% from 1Q 2022). Net income: ₪214.0k (down 98% from 1Q 2022). Profit margin: 0.2% (down from 15% in 1Q 2022). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has increased by 114% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Mar 27Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₪7.76, the stock trades at a trailing P/E ratio of 10.6x. Average forward P/E is 18x in the Pharmaceuticals industry in Asia. Total loss to shareholders of 52% over the past three years.Valuation Update With 7 Day Price Move • Mar 12Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₪7.32, the stock trades at a trailing P/E ratio of 10x. Average forward P/E is 18x in the Pharmaceuticals industry in Asia. Total loss to shareholders of 22% over the past three years.Valuation Update With 7 Day Price Move • Feb 21Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₪10.13, the stock trades at a trailing P/E ratio of 13.9x. Average forward P/E is 19x in the Pharmaceuticals industry in Asia. Total loss to shareholders of 36% over the past three years.分析記事 • Feb 16These 4 Measures Indicate That InterCure (TLV:INCR) Is Using Debt Reasonably WellHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Reported Earnings • Nov 16Third quarter 2022 earnings released: EPS: ₪0.16 (vs ₪0.04 loss in 3Q 2021)Third quarter 2022 results: EPS: ₪0.16 (up from ₪0.04 loss in 3Q 2021). Revenue: ₪100.6m (up 63% from 3Q 2021). Net income: ₪7.26m (up ₪8.90m from 3Q 2021). Profit margin: 7.2% (up from net loss in 3Q 2021). The move to profitability was driven by higher revenue. Revenue is forecast to grow 26% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.分析記事 • Sep 19What InterCure Ltd.'s (TLV:INCR) P/E Is Not Telling YouWith a price-to-earnings (or "P/E") ratio of 27.8x InterCure Ltd. ( TLV:INCR ) may be sending very bearish signals at...分析記事 • Aug 22Here's Why InterCure (TLV:INCR) Can Manage Its Debt ResponsiblySome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Reported Earnings • Aug 18Second quarter 2022 earnings released: EPS: ₪0.35 (vs ₪0.14 in 2Q 2021)Second quarter 2022 results: EPS: ₪0.35 (up from ₪0.14 in 2Q 2021). Revenue: ₪95.3m (up 111% from 2Q 2021). Net income: ₪15.6m (up 153% from 2Q 2021). Profit margin: 16% (up from 14% in 2Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 45%, compared to a 24% growth forecast for the Pharmaceuticals industry in Israel. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.Reported Earnings • May 18First quarter 2022 earnings released: EPS: ₪0.38 (vs ₪0.12 in 1Q 2021)First quarter 2022 results: EPS: ₪0.38 (up from ₪0.12 in 1Q 2021). Revenue: ₪87.2m (up 164% from 1Q 2021). Net income: ₪13.4m (up 412% from 1Q 2021). Profit margin: 15% (up from 7.9% in 1Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 77%, compared to a 23% growth forecast for the industry in Israel. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.Reported Earnings • Apr 07Full year 2021 earnings released: EPS: ₪0.12 (vs ₪1.47 loss in FY 2020)Full year 2021 results: EPS: ₪0.12 (up from ₪1.47 loss in FY 2020). Revenue: ₪219.7m (up 238% from FY 2020). Net income: ₪4.69m (up ₪41.9m from FY 2020). Profit margin: 2.1% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Over the next year, revenue is forecast to grow 93%, compared to a 22% growth forecast for the pharmaceuticals industry in Israel. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 23% per year, which means it is performing significantly worse than earnings.Recent Insider Transactions • Mar 22Insider recently sold ₪1.4m worth of stockOn the 16th of March, Yael Fegel sold around 20k shares on-market at roughly ₪68.94 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₪957k more than they bought in the last 12 months.Board Change • Mar 02Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent External Director Gideon Hirschfeld was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.分析記事 • Feb 14InterCure (TLV:INCR) Seems To Use Debt Quite SensiblyLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Valuation Update With 7 Day Price Move • Feb 13Investor sentiment improved over the past weekAfter last week's 24% share price gain to ₪24.45, the stock trades at a trailing P/E ratio of 65x. Average forward P/E is 19x in the Pharmaceuticals industry in Asia. Total loss to shareholders of 53% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₪42.97 per share.Reported Earnings • Nov 17Third quarter 2021 earnings released: ₪0.04 loss per share (vs ₪0.067 profit in 3Q 2020)The company reported a decent third quarter result with improved revenues, although earnings and control over costs were weaker. Third quarter 2021 results: Revenue: ₪61.7m (up 174% from 3Q 2020). Net loss: ₪1.64m (down 195% from profit in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings.分析記事 • Sep 11These 4 Measures Indicate That InterCure (TLV:INCR) Is Using Debt Reasonably WellThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Valuation Update With 7 Day Price Move • Sep 02Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₪24.00, the stock trades at a trailing P/E ratio of 27.4x. Average forward P/E is 19x in the Pharmaceuticals industry in Asia. Total returns to shareholders of 208% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₪41.34 per share.Reported Earnings • Aug 18Second quarter 2021 earnings releasedThe company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: ₪45.2m (up 304% from 2Q 2020). Net income: ₪6.19m (up ₪7.17m from 2Q 2020). Profit margin: 14% (up from net loss in 2Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has increased by 75% per year, which means it is well ahead of earnings.Valuation Update With 7 Day Price Move • Jun 04Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₪28.20, the stock trades at a trailing P/E ratio of 45.8x. Average forward P/E is 22x in the Medical Equipment industry in Israel. Total returns to shareholders of 1,377% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₪41.48 per share.Recent Insider Transactions • May 21Insider recently bought ₪437k worth of stockOn the 17th of May, Alexander Rabinovich bought around 20k shares on-market at roughly ₪21.85 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.Reported Earnings • Apr 04Full year 2020 earnings released: ₪0.32 loss per share (vs ₪0.029 loss in FY 2019)The company reported a decent full year result with improved revenues, although losses increased and control over costs was weaker. Full year 2020 results: Revenue: ₪65.0m (up ₪56.1m from FY 2019). Net loss: ₪37.2m (loss widened ₪34.2m from FY 2019). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 195 percentage points per year, which is a significant difference in performance.分析記事 • Mar 08What Percentage Of InterCure Ltd (TLV:INCR) Shares Do Insiders Own?A look at the shareholders of InterCure Ltd ( TLV:INCR ) can tell us which group is most powerful. Generally speaking...お知らせ • Jan 28+ 1 more updateInterCure Ltd Announces Executive ChangesSubversive Real Estate Acquisition REIT LP (SPAC) announced its qualifying transaction to combine with InterCure Ltd. (dba Canndoc). Following the closing of the Transaction, Canndoc will continue to be led by its experienced executive team with deep knowledge of the cannabis industry, and operational expertise in the agriculture technology and pharmaceutical industries: Rami Levy, Chief Operating Officer and Moshe Gavrilov, Chief Marketing Officer. Board of Directors and Medical Advisory Board is expected to include: Ehud Barak, former Prime Minister of Israel to serve as Chairman, Michael Auerbach, Founder, Subversive Capital, Prof. Zvi Bentwich, MD, PHD, Professor of Microbiology, Immunology and Genetics, and Head of the Center for Emerging Tropical Diseases & Aids, Ben Gurion University and Prof. Eitan Friedman, Dir. and Founder Suzanne Levy-Gertner Oncogenetics Unit, Sheba Medical Center.Is New 90 Day High Low • Jan 26New 90-day high: ₪5.53The company is up 64% from its price of ₪3.37 on 28 October 2020. The Israeli market is up 23% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 20% over the same period.分析記事 • Jan 12Shareholders Are Raving About How The InterCure (TLV:INCR) Share Price Increased 936%We think all investors should try to buy and hold high quality multi-year winners. While not every stock performs well...Is New 90 Day High Low • Dec 29New 90-day high: ₪3.92The company is up 22% from its price of ₪3.20 on 30 September 2020. The Israeli market is up 26% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Medical Equipment industry, which is up 4.0% over the same period.お知らせ • Dec 12Charlotte's Web, Inc. Signs Exclusive Distribution Agreement in Israel with InterCure Ltd and Canndoc LtdCharlotte's Web Holdings, Inc. announced that Charlotte's Web, Inc. has signed an exclusive distribution agreement in Israel with InterCure Ltd. and Canndoc Ltd. Canndoc has been a pioneer in pharmaceutical-grade cannabis for more than 13 years. Its GMP-approved medical cannabis products are sold in pharmacies in Israel, and it holds international cultivation and distribution agreements in the European Union. Selected Charlotte's Web hemp extract wellness products will be available to the Israeli public through Canndoc or another subsidiary of InterCure. Charlotte's Web and InterCure also are considering future distribution agreements in certain European countries. The two companies will also explore opportunities such as clinical trials, product development and manufacturing in Israel.分析記事 • Dec 04Is InterCure (TLV:INCR) Using Debt Sensibly?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Is New 90 Day High Low • Oct 12New 90-day high: ₪3.80The company is up 14% from its price of ₪3.32 on 14 July 2020. The Israeli market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 2.0% over the same period.お知らせ • Sep 26+ 1 more updateInterCure Ltd. (TASE:INCR) completed the acquisition of additional 7.43% stake in Regenera Pharma Ltd. from Bamot Investments (1996) Ltd.InterCure Ltd. (TASE:INCR) signed an agreement to acquire additional 7.43% stake in Regenera Pharma Ltd. from Bamot Investments (1996) Ltd. for ILS 3 million on September 11, 2016. As per the consideration, InterCure will issue its 5.5 million shares and 1 million warrants at a strike price of ILS 1 each for three years to Bamot. According to the deal conditions, the shares to be allotted to Bamot will be locked, and cannot be negotiated in the exchange for a period of 6 months. As of September 27, 2016 all the pre-conditions have been fulfilled. InterCure Ltd. (TASE:INCR) completed the acquisition of additional 7.43% stake in Regenera Pharma Ltd. from Bamot Investments (1996) Ltd. on September 27, 2016. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、InterCure は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測TASE:INCR - アナリストの将来予測と過去の財務データ ( )ILS Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2025270-361317N/A9/30/2025257-53-33N/A6/30/2025243-71-19-11N/A3/31/2025241-69-45-39N/A12/31/2024239-68-72-67N/A9/30/2024256-67N/AN/AN/A6/30/2024273-66N/AN/AN/A3/31/2024312-61-25-23N/A12/31/2023356-62-56-54N/A9/30/2023388-20N/AN/AN/A6/30/202341521N/AN/AN/A3/31/202340832-18-4N/A12/31/2022389453251N/A9/30/202236333-617N/A6/30/202232424424N/A3/31/202227415725N/A12/31/202122051630N/A9/30/2021167172032N/A6/30/2021128201225N/A3/31/20219413219N/A12/31/202065-37-138N/A9/30/202040-63-25-3N/A6/30/202020-80-42-16N/A3/31/202011-91-47-13N/A12/31/20199-6-40-12N/A9/30/201977N/A-11N/A6/30/2019518N/A-5N/A3/31/2019227N/A-3N/A12/31/2018N/A-13N/A-1N/A9/30/2018N/A-10N/A-1N/A6/30/2018N/A-8N/A-1N/A3/31/2018N/A-7N/A-1N/A12/31/2017N/A-6N/A-1N/A9/30/2017N/A-4N/A-1N/A6/30/2017N/A-2N/A-1N/A3/31/2017N/A-2N/A-1N/A12/31/2016N/A0N/A-1N/A9/30/201600N/A-1N/A6/30/20160-1N/A-1N/A3/31/201610N/A-1N/A12/31/20151-2N/A-2N/A9/30/20152-1N/A-1N/A6/30/20153-2N/A-1N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: INCRの予測収益成長が 貯蓄率 ( 3.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: INCRの収益がIL市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: INCRの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: INCRの収益がIL市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: INCRの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: INCRの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/23 22:28終値2026/05/20 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋InterCure Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Matt BottomleyCanaccord GenuityVivien AzerTD Cowen
Reported Earnings • May 05Full year 2025 earnings released: ₪0.66 loss per share (vs ₪1.48 loss in FY 2024)Full year 2025 results: ₪0.66 loss per share (improved from ₪1.48 loss in FY 2024). Revenue: ₪270.2m (up 13% from FY 2024). Net loss: ₪35.7m (loss narrowed 47% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has only fallen by 33% per year, which means it has not declined as severely as earnings.
New Risk • Apr 26New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 25% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Share price has been volatile over the past 3 months (7.3% average weekly change). Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (₪140.8m market cap, or US$47.2m).
New Risk • Apr 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Israeli stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 25% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.1% average weekly change). Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (₪148.7m market cap, or US$49.5m).
分析記事 • Jan 14Why Investors Shouldn't Be Surprised By InterCure Ltd.'s (TLV:INCR) 29% Share Price PlungeUnfortunately for some shareholders, the InterCure Ltd. ( TLV:INCR ) share price has dived 29% in the last thirty days...
分析記事 • Dec 24We Discuss Why InterCure Ltd.'s (TLV:INCR) CEO Compensation May Be Closely ReviewedKey Insights InterCure's Annual General Meeting to take place on 30th of December Total pay for CEO Alex Rabinovich...
New Risk • Dec 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Israeli stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 25% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.5% average weekly change). Shareholders have been diluted in the past year (19% increase in shares outstanding). Market cap is less than US$100m (₪224.3m market cap, or US$70.0m).
お知らせ • Nov 26InterCure Ltd., Annual General Meeting, Dec 30, 2025InterCure Ltd., Annual General Meeting, Dec 30, 2025. Location: amit, pollak, matalon & co., at apm house, 18 raoul wallenberg st., building d, 6th floor, ramat hachayal., tel aviv Israel
Reported Earnings • Oct 11First half 2025 earnings released: ₪0.03 loss per share (vs ₪0.03 profit in 1H 2024)First half 2025 results: ₪0.03 loss per share (down from ₪0.03 profit in 1H 2024). Revenue: ₪130.0m (up 3.4% from 1H 2024). Net loss: ₪1.70m (down 219% from profit in 1H 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 61 percentage points per year, which is a significant difference in performance.
Board Change • Aug 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. Non-Executive Director Alon Granot was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • May 02InterCure Ltd. announced delayed 20-F filingOn 05/01/2025, InterCure Ltd. announced that they will be unable to file their next 20-F by the deadline required by the SEC.
お知らせ • Feb 13Intercure Names Announces Board Changes, Effective February 13, 2025InterCure Ltd. announces that Mr. Ehud Barak will step down as Chairman of the board of directors of the Company, effective February 13, 2025. He will be succeeded by Mr. Alexander Rabinovich, who has successfully led the Company as CEO for the past five years, executing hundreds of percentages of profitable growth, building strategic international partnerships, and establishing InterCure's position as a leader in pharmaceutical cannabis. Mr. Barak, who is marking his 83rd birthday, has decided to pursue personal endeavors after six years of service as Chairman of their Board. InterCure extends its deepest appreciation to Mr. Barak for his contributions, which has helped guide the Company's progress alongside its executive team.
お知らせ • Nov 26InterCure Ltd., Annual General Meeting, Dec 30, 2024InterCure Ltd., Annual General Meeting, Dec 30, 2024. Location: at the offices of the companys attorneys, doron tikotzky kantor gutman & amit gross., 7 metsada st., b.s.r tower 4, 33 floor, bnei brak Israel
お知らせ • May 03+ 1 more updateInterCure Ltd. announced delayed 20-F filingOn 05/01/2024, InterCure Ltd. announced that they will be unable to file their next 20-F by the deadline required by the SEC.
お知らせ • Feb 15InterCure Ltd. Announces Resignation of Rami Levy as Chief of OperationsInterCure Ltd. announced that effective February 7, 2024, Rami Levy, resigned as the Chief of Operations of the company due to personal reasons. Mr. Levy’s resignation was not the result of any disagreement with the Company, or due to any matter relating to the Company’s operations, policies or practices.
お知らせ • Nov 09InterCure Ltd., Annual General Meeting, Dec 14, 2023InterCure Ltd., Annual General Meeting, Dec 14, 2023, at 16:00 Israel Standard Time. Location: the offices of the Company's attorneys, Doron Tikotzky Kantor Gutman Nass & Amit Gross., 7 Metsada St., lB.S.R Tower 4, 33 Floor, Bnei Brak, Israe Bnei Brak Israel Agenda: To approve the re-election of Ehud Barak, Alexander Rabinovich, and Alon Granot, to the board of directors of the Company, each until the next annual general meeting of shareholders ; to approve, upon the recommendation of the Company's audit committee and of the Board of Directors, the re-election of David Salton to our Board of Directors, as an independent director until the next annual general meeting of shareholders; to approve the re-appointment of Somekh Chaikin, a member firm of KPMG International (the "Auditors"), as the Company's independent registered public accounting firm for the year ending December 31, 2023, and to authorize the Board of Directors, upon the recommendation of the Audit Committee, to determine the Auditors' remuneration to be fixed in accordance with the volume and nature of their services to the Company for such fiscal year; and to consider other matters if any.
お知らせ • Nov 01InterCure Ltd. Wins Cannolam Arbitration ProceedingInterCure Ltd. reported that, further to the Company's press release issued on August 31, 2023, in which the Company reported that the Tel Aviv-Jaffa District Court dismissed the lawsuit that filed against the Company by minority shareholders of its subsidiary, Cannolam Ltd. (‘Cannolam’), and the parties agreed on a binding arbitration process (the ‘Arbitration’), in which the amount owed to the Company and the parties will be determined and paid as part of a full separation process, the Company hereby reports that the Arbitration has been concluded, and the arbitrator has decided in favor of the Company on most of the claims presented to him by the Company, while rejecting almost all of the claims presented by the minority shareholders. Additionally, the arbitrator determined that Cannolam owes InterCure significant amounts (tens of NIS millions), which InterCure has claimed as part of the Arbitration, in recognition of InterCure's ongoing support to Cannolam. The minority shareholders did not transfer their part of the Cannolam debt owed to InterCure, and as a result, in accordance with the Arbitration decision, their shares in Cannolam were transferred to InterCure. As a result, as of the date hereof, InterCure now holds 100% of the shares in Cannolam, which has the exclusive right to use the ‘CookiesTM’ brand in Israel and other territories. Cannolam is the leading pharmacy chain specializing in dispensing pharmaceutical-grade cannabis. It operates under GivolTM and CookiesTM branded locations.
お知らせ • Jul 12InterCure Announces Proposed Voluntary Delisting from the Toronto Stock ExchangeInterCure Ltd. ("InterCure" or the "Company"), announced that its board of directors (“Board”) has approved the voluntarily delisting of the Company’s common shares (“Shares”) from the Toronto Stock Exchange (the “TSX”) (the “Delisting”). The Company has decided to delist from the TSX after concluding that maintaining the listing does not offer substantial benefits to the Company and its shareholders. The Shares are currently listed on the NASDAQ and the Tel Aviv Stock Exchange, in addition to them being listed on the TSX. After a careful review of the trading volume data relating to the Shares, the Board has concluded that the trading volume on the TSX in insufficient to justify the continued listing. The Issuer will, however, remain a “reporting issuer” under applicable Canadian securities laws and continue to provide regular comprehensive disclosure pursuant to National Instrument 71-102 – Continues Disclosure and Other Exemptions Relating to Foreign Issuers as a “SEC Foreign Issuer”. Most brokers in Canada, including discount and online brokers, have the ability to buy and sell securities listed on the NASDAQ. Therefore, the Company’s NASDAQ listing will continue to provide shareholders with the same accessibility to trade the Company’s common shares. The value of the Company’s common shares is not related to or dependent on the TSX listing. Shareholders holding common shares in Canadian brokerage accounts should contact their brokers to confirm how to trade the Company’s shares on the NASDAQ. The Company has applied to the TSX to delist the Shares from the TSX at the end of the trading session on August 14, 2023. The Delisting is subject to the approval of the TSX. As per Section 720 of the TSX Company Manual, shareholder approval is not required as an acceptable alternate market exists for the listed securities. In connection with the Delisting, in accordance with Israeli securities laws, the Company will seek the approval of its shareholders, at a special meeting of shareholders called on August 14, 2023, to rely on the dual listing of the Shares on the Nasdaq Global Market and on Tel Aviv Stock Exchange for the purposes of compliance with Israeli securities laws, in accordance with Section 35FF of the Israeli Securities Law, 5728-1968.
お知らせ • Jun 15Better Files A Lawsuit Against InterCure and its Chairman Ehud BarakMedical cannabis company Better is suing InterCure, a company headed by Ehud Barak, for $35 million. A lawsuit has been filed against InterCure and its management, adding to a series of lawsuits recently filed against the company's conduct. According to Better, the lawsuit stems from InterCure's alleged attempts to push competitors like Better and other cannabis companies out of the market. Better claims that InterCure has a history of misrepresenting facts to acquisition companies for the purpose of merging and abusing its power in the deal. Better also claims that InterCure has the bad faith of engaging in predatory activities that drain the financial reserves of the acquisition targets. The lawsuit addresses the actions taken by InterCure's executives during the negotiations with Better, allegedly including making false representations, exerting pressure to transfer commercial materials, damaging production capabilities and harming the company's customers, assets, and means. Better is asking the court for a number of remedies outlined in its lawsuit, as compensation for InterCure's damages to Better during negotiations.
Reported Earnings • May 17First quarter 2023 earnings released: EPS: ₪0.005 (vs ₪0.38 in 1Q 2022)First quarter 2023 results: EPS: ₪0.005 (down from ₪0.38 in 1Q 2022). Revenue: ₪106.2m (up 22% from 1Q 2022). Net income: ₪214.0k (down 98% from 1Q 2022). Profit margin: 0.2% (down from 15% in 1Q 2022). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has increased by 114% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Mar 27Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₪7.76, the stock trades at a trailing P/E ratio of 10.6x. Average forward P/E is 18x in the Pharmaceuticals industry in Asia. Total loss to shareholders of 52% over the past three years.
Valuation Update With 7 Day Price Move • Mar 12Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₪7.32, the stock trades at a trailing P/E ratio of 10x. Average forward P/E is 18x in the Pharmaceuticals industry in Asia. Total loss to shareholders of 22% over the past three years.
Valuation Update With 7 Day Price Move • Feb 21Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₪10.13, the stock trades at a trailing P/E ratio of 13.9x. Average forward P/E is 19x in the Pharmaceuticals industry in Asia. Total loss to shareholders of 36% over the past three years.
分析記事 • Feb 16These 4 Measures Indicate That InterCure (TLV:INCR) Is Using Debt Reasonably WellHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Reported Earnings • Nov 16Third quarter 2022 earnings released: EPS: ₪0.16 (vs ₪0.04 loss in 3Q 2021)Third quarter 2022 results: EPS: ₪0.16 (up from ₪0.04 loss in 3Q 2021). Revenue: ₪100.6m (up 63% from 3Q 2021). Net income: ₪7.26m (up ₪8.90m from 3Q 2021). Profit margin: 7.2% (up from net loss in 3Q 2021). The move to profitability was driven by higher revenue. Revenue is forecast to grow 26% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
分析記事 • Sep 19What InterCure Ltd.'s (TLV:INCR) P/E Is Not Telling YouWith a price-to-earnings (or "P/E") ratio of 27.8x InterCure Ltd. ( TLV:INCR ) may be sending very bearish signals at...
分析記事 • Aug 22Here's Why InterCure (TLV:INCR) Can Manage Its Debt ResponsiblySome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Reported Earnings • Aug 18Second quarter 2022 earnings released: EPS: ₪0.35 (vs ₪0.14 in 2Q 2021)Second quarter 2022 results: EPS: ₪0.35 (up from ₪0.14 in 2Q 2021). Revenue: ₪95.3m (up 111% from 2Q 2021). Net income: ₪15.6m (up 153% from 2Q 2021). Profit margin: 16% (up from 14% in 2Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 45%, compared to a 24% growth forecast for the Pharmaceuticals industry in Israel. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
Reported Earnings • May 18First quarter 2022 earnings released: EPS: ₪0.38 (vs ₪0.12 in 1Q 2021)First quarter 2022 results: EPS: ₪0.38 (up from ₪0.12 in 1Q 2021). Revenue: ₪87.2m (up 164% from 1Q 2021). Net income: ₪13.4m (up 412% from 1Q 2021). Profit margin: 15% (up from 7.9% in 1Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 77%, compared to a 23% growth forecast for the industry in Israel. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.
Reported Earnings • Apr 07Full year 2021 earnings released: EPS: ₪0.12 (vs ₪1.47 loss in FY 2020)Full year 2021 results: EPS: ₪0.12 (up from ₪1.47 loss in FY 2020). Revenue: ₪219.7m (up 238% from FY 2020). Net income: ₪4.69m (up ₪41.9m from FY 2020). Profit margin: 2.1% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Over the next year, revenue is forecast to grow 93%, compared to a 22% growth forecast for the pharmaceuticals industry in Israel. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 23% per year, which means it is performing significantly worse than earnings.
Recent Insider Transactions • Mar 22Insider recently sold ₪1.4m worth of stockOn the 16th of March, Yael Fegel sold around 20k shares on-market at roughly ₪68.94 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₪957k more than they bought in the last 12 months.
Board Change • Mar 02Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent External Director Gideon Hirschfeld was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
分析記事 • Feb 14InterCure (TLV:INCR) Seems To Use Debt Quite SensiblyLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Valuation Update With 7 Day Price Move • Feb 13Investor sentiment improved over the past weekAfter last week's 24% share price gain to ₪24.45, the stock trades at a trailing P/E ratio of 65x. Average forward P/E is 19x in the Pharmaceuticals industry in Asia. Total loss to shareholders of 53% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₪42.97 per share.
Reported Earnings • Nov 17Third quarter 2021 earnings released: ₪0.04 loss per share (vs ₪0.067 profit in 3Q 2020)The company reported a decent third quarter result with improved revenues, although earnings and control over costs were weaker. Third quarter 2021 results: Revenue: ₪61.7m (up 174% from 3Q 2020). Net loss: ₪1.64m (down 195% from profit in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings.
分析記事 • Sep 11These 4 Measures Indicate That InterCure (TLV:INCR) Is Using Debt Reasonably WellThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Valuation Update With 7 Day Price Move • Sep 02Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₪24.00, the stock trades at a trailing P/E ratio of 27.4x. Average forward P/E is 19x in the Pharmaceuticals industry in Asia. Total returns to shareholders of 208% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₪41.34 per share.
Reported Earnings • Aug 18Second quarter 2021 earnings releasedThe company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: ₪45.2m (up 304% from 2Q 2020). Net income: ₪6.19m (up ₪7.17m from 2Q 2020). Profit margin: 14% (up from net loss in 2Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has increased by 75% per year, which means it is well ahead of earnings.
Valuation Update With 7 Day Price Move • Jun 04Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₪28.20, the stock trades at a trailing P/E ratio of 45.8x. Average forward P/E is 22x in the Medical Equipment industry in Israel. Total returns to shareholders of 1,377% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₪41.48 per share.
Recent Insider Transactions • May 21Insider recently bought ₪437k worth of stockOn the 17th of May, Alexander Rabinovich bought around 20k shares on-market at roughly ₪21.85 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
Reported Earnings • Apr 04Full year 2020 earnings released: ₪0.32 loss per share (vs ₪0.029 loss in FY 2019)The company reported a decent full year result with improved revenues, although losses increased and control over costs was weaker. Full year 2020 results: Revenue: ₪65.0m (up ₪56.1m from FY 2019). Net loss: ₪37.2m (loss widened ₪34.2m from FY 2019). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 195 percentage points per year, which is a significant difference in performance.
分析記事 • Mar 08What Percentage Of InterCure Ltd (TLV:INCR) Shares Do Insiders Own?A look at the shareholders of InterCure Ltd ( TLV:INCR ) can tell us which group is most powerful. Generally speaking...
お知らせ • Jan 28+ 1 more updateInterCure Ltd Announces Executive ChangesSubversive Real Estate Acquisition REIT LP (SPAC) announced its qualifying transaction to combine with InterCure Ltd. (dba Canndoc). Following the closing of the Transaction, Canndoc will continue to be led by its experienced executive team with deep knowledge of the cannabis industry, and operational expertise in the agriculture technology and pharmaceutical industries: Rami Levy, Chief Operating Officer and Moshe Gavrilov, Chief Marketing Officer. Board of Directors and Medical Advisory Board is expected to include: Ehud Barak, former Prime Minister of Israel to serve as Chairman, Michael Auerbach, Founder, Subversive Capital, Prof. Zvi Bentwich, MD, PHD, Professor of Microbiology, Immunology and Genetics, and Head of the Center for Emerging Tropical Diseases & Aids, Ben Gurion University and Prof. Eitan Friedman, Dir. and Founder Suzanne Levy-Gertner Oncogenetics Unit, Sheba Medical Center.
Is New 90 Day High Low • Jan 26New 90-day high: ₪5.53The company is up 64% from its price of ₪3.37 on 28 October 2020. The Israeli market is up 23% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 20% over the same period.
分析記事 • Jan 12Shareholders Are Raving About How The InterCure (TLV:INCR) Share Price Increased 936%We think all investors should try to buy and hold high quality multi-year winners. While not every stock performs well...
Is New 90 Day High Low • Dec 29New 90-day high: ₪3.92The company is up 22% from its price of ₪3.20 on 30 September 2020. The Israeli market is up 26% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Medical Equipment industry, which is up 4.0% over the same period.
お知らせ • Dec 12Charlotte's Web, Inc. Signs Exclusive Distribution Agreement in Israel with InterCure Ltd and Canndoc LtdCharlotte's Web Holdings, Inc. announced that Charlotte's Web, Inc. has signed an exclusive distribution agreement in Israel with InterCure Ltd. and Canndoc Ltd. Canndoc has been a pioneer in pharmaceutical-grade cannabis for more than 13 years. Its GMP-approved medical cannabis products are sold in pharmacies in Israel, and it holds international cultivation and distribution agreements in the European Union. Selected Charlotte's Web hemp extract wellness products will be available to the Israeli public through Canndoc or another subsidiary of InterCure. Charlotte's Web and InterCure also are considering future distribution agreements in certain European countries. The two companies will also explore opportunities such as clinical trials, product development and manufacturing in Israel.
分析記事 • Dec 04Is InterCure (TLV:INCR) Using Debt Sensibly?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Is New 90 Day High Low • Oct 12New 90-day high: ₪3.80The company is up 14% from its price of ₪3.32 on 14 July 2020. The Israeli market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 2.0% over the same period.
お知らせ • Sep 26+ 1 more updateInterCure Ltd. (TASE:INCR) completed the acquisition of additional 7.43% stake in Regenera Pharma Ltd. from Bamot Investments (1996) Ltd.InterCure Ltd. (TASE:INCR) signed an agreement to acquire additional 7.43% stake in Regenera Pharma Ltd. from Bamot Investments (1996) Ltd. for ILS 3 million on September 11, 2016. As per the consideration, InterCure will issue its 5.5 million shares and 1 million warrants at a strike price of ILS 1 each for three years to Bamot. According to the deal conditions, the shares to be allotted to Bamot will be locked, and cannot be negotiated in the exchange for a period of 6 months. As of September 27, 2016 all the pre-conditions have been fulfilled. InterCure Ltd. (TASE:INCR) completed the acquisition of additional 7.43% stake in Regenera Pharma Ltd. from Bamot Investments (1996) Ltd. on September 27, 2016.